Company Encyclopedia
View More
name
Invesco Nasdaq Biotechnology ETF
IBBQ.US
News
View More

Top 10 US Stock Losers (12.18)

Inspire Medical(INSP) fell 19.45%, with a trading turnover 620.3 Million USD, and a year-to-date fell 48.6%. Insmed(INSM) fell 16.08%, with a trading turnover 2.2 Billion USD, and a year-to-date rose 141.2%. Canopy Growth(CGC) fell 11.98%, with a trading turnover 450.3 Million USD, and a year-to-date fell 38.3%.

Top Gainers & Losers·
US
INSP
-19.45%
US
INSM
-16.08%
US
CGC
-11.98%
Top Gainers & Losers·
US
INSP
-19.45%
US
INSM
-16.08%
US
CGC
-11.98%

Top 3 Trending Stocks, According to Analysts – 12/18/2025

Analysts have identified Micron (MU), Insmed (INSM), and General Mills (GIS) as the top trending stocks over the past 72 hours. Micron received 20 ratings after strong fiscal Q1 results, Insmed got 14 ratings despite a study failure, and General Mills was rated 13 times after surpassing fiscal Q2 estimates. TipRanks offers tools like Smart Portfolio for data-driven investment decisions.

Tip Ranks·
US
MU
+10.21%
US
GIS
+0.21%
US
INSM
-16.08%
Tip Ranks·
US
MU
+10.21%
US
GIS
+0.21%
US
INSM
-16.08%

13:58 ET Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies

Niowave Inc. has expanded its supply agreement with AstraZeneca to deliver Actinium-225 for 10 years. This agreement supports AstraZeneca's development of radioconjugate therapies, which target and destroy cancer cells. Niowave's technology ensures a reliable supply of this critical isotope, crucial for advancing cancer treatments. The expansion highlights Niowave's role in medical radioisotope production and AstraZeneca's commitment to innovative cancer therapies.

prnewswire·
US
AZN
+0.83%
UK
AZN
0.00%
prnewswire·
US
AZN
+0.83%
UK
AZN
0.00%

Insmed Stock (INSM) Sinks 18% as Analysts Cut Targets after Trial Failure — What's Next?

Insmed's stock dropped 18% after the failure of its Phase 2b BiRCh trial for CRSsNP. Analysts cut price targets but remain optimistic, with targets still implying significant upside. Despite the trial setback, analysts see potential in Insmed's other drug trials and commercial launches. Insmed maintains a Strong Buy consensus rating, with an average price target suggesting a 31% upside.

Tip Ranks·
US
INSM
-16.08%
Tip Ranks·
US
INSM
-16.08%

Insmed (NASDAQ:INSM) Given New $241.00 Price Target at TD Cowen

TD Cowen reduced Insmed's price target from $269.00 to $241.00, maintaining a "buy" rating. Insmed's stock fell 16% to $166.77, with a potential upside of 44.51% from the new target. Insmed reported a quarterly loss of $1.75 per share, missing estimates. Insiders sold shares, decreasing their ownership. Institutional investors adjusted their positions in the company.

Market Beat·
US
INSM
-16.08%
Market Beat·
US
INSM
-16.08%
© 2025 Longbridge｜Disclaimer